Print/Mobile View

ASN Mobile

Menu Links

Menu

ASN News Feed

Old Flash player or no Flash player detected. Please click the link below to download the latest version of Adobe Flash Player.

Get macromedia Flash Player

grants and funding

NIH Funding Opportunities

Ancillary Studies of Kidney Disease

The NIDDK is seeking investigator-initiated research project applications for ancillary studies to ongoing or completed clinical trials and epidemiological studies of kidney disease as well as clinical trials and epidemiological studies for other diseases or populations that lend themselves to the study of kidney disease. View the program announcement.


NIH Loan Repayment Programs

The NIH Loan Repayment Programs (LRP) are designed to attract doctoral-level professionals to careers in clinical, pediatric, health disparities, or contraceptive and infertility research. View the program announcement.


Notice of the Availability of Concept Development Administrative Supplements for the Kidney Disease Clinical Studies Initiative

In conjunction with the NIH, the ASN supported the development of a program to encourage the study of kidney disease, its complications and treatment in patients. This program is funded through The Concept Development Supplements. The goal is to provide support for planning and writing an investigator- initiated application for clinical studies in kidney disease. The usual supplement is $50,000 direct costs. The NIDDK website contains details. Please note that we encourage a wide range of applications for studies and especially applications that will lead to RO1, R21, and R33 applications under $500,000 direct cost per year. Most importantly, approximately 10 of 25 to 30 requests for the $50,000 for writing and planning were funded last year.


News Articles

More News
Need help?

ASN Contact Info

American Society of Nephrology
1725 I Street, NW
Suite 510
Washington, DC 20006

tel: 202-659-0599
fax: 202-659-0709
email@asn-online.org
Translate This Page

The ASN website can be translated into a number of different
languages. For more information view the disclaimer.

Close | Disclaimer